Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Table. 1.

Ongoing or planned clinical trial for COVID-19 vaccine up to 11 November 2020

Candidate Type Phase Study design Volunteer Country Reference
Moderna mRNA-1273 RNA 3 Double-blind randomized 30000 USA NCT04470427
WIBP vaccine Inactivated 3 Double-blind randomized 45,000 Bahrain, Jordan, Egypt, UAE NCT04510207
Sinovac CoronaVac Inactivated 3 Double-blind randomized 13,060 Brazil NCT04456595
Oxford ChAdOx1-S Non-replicating viral vector 3 Double-blind randomized 40,051 USA, Chile, Peru NCT04516746
Novavax NVX-CoV2373 Protein subunit 3 Double-blind randomized 30,000 USA, Mexico, Puerto Rico NCT04611802
Novavax NVX-CoV2373 Protein subunit 3 Double-blind randomized 9,000 UK NCT04583995
Moderna mRNA-1273 RNA 3 Double-blind randomized 30,000 USA NCT04470427
Cansino Ad5-nCoV Non-replicating viral vector 3 Double-blind randomized 40,000 Pakistan NCT04526990
BIBP/ Sinopharm BBIBP-CorV Inactivated 3 Double-blind randomized 3,000 Argentina NCT04560881
Oxford ChAdOx1-S Non-replicating viral vector 2/3 Single-blind randomized 12,390 UK NCT04400838
BioNTech BNT162 RNA 2/3 Dose-finding, double-blind randomized 43,998 USA, Argentina, Brazil, others NCT04368728
BioNTech BNT162 RNA 2/3 Dose-finding, open-label non-randomized 43,998 USA, Argentina, Brazil, others NCT04380701
AZLB protein subunit vaccine Protein subunit 2 Double-blind randomized 900 China NCT04466085
Novavax NVX-CoV2373 Protein subunit 2 Single-blind randomized 4,400 South Africa NCT04533399
Curevac CVnCoV RNA 2 Dose-confirmation,double-blind, randomized 691 Peru NCT04515147
Oxford ChAdOx1-S Non-replicating viral vector 1/2 Double-blind randomized 2000 South Africa NCT04444674
WIBP vaccine Inactivated 1/2 Dose-finding, double-blind randomized 1,264 China ChiCTR2000031809
Bharat Covaxin Inactivated 1/2 Double-blind randomized 755 India NCT04471519
Oxford ChAdOx1-S Non-replicating viral vector 1/2 Single-blind randomized 1,090 UK NCT04324606
Zydus Cadila ZyCoV-D DNA 1/2 Double-blind randomized 1048 India CTRI/2020/07/026352
CAMS vaccine Inactivated 1/2 Dose-finding, double-blind randomized 942 China NCT04412538
Sinovac CoronaVac Inactivated 1/2 Dose-finding, double-blind randomized 744 China NCT04352608
Cansino Ad5-nCoV Non-replicating viral vector 1/2 Dose-finding, double-blind randomized 696 Canada NCT04398147
CAMS vaccine Inactivated 1/2 Double-blind randomized 471 China NCT04470609
Sinovac CoronaVac Inactivated 1/2 Dose-finding, double-blind randomized 422 China NCT04383574
Genexine GX-19 DNA 1/2 Dose-finding, double-blind randomized 210 Republic of Korea NCT04445389
Aivita AV-COVID-19 Other 1/2 Dose-finding, double-blind randomized 180 USA NCT04386252
KBP-COVID-19 Protein subunit 1/2 Observer-blind, dose-finding randomized 180 Not Provided NCT04473690
Inovio INO-4800 DNA 1/2 Dose-finding, Open-label (A), double-blind (B) randomized 160 Republic of Korea NCT04447781
Arcturus ARCT-021 RNA 1/2 Double-blind randomized 92 Singapore NCT04480957
AnGes AG0301-COVID19 DNA 1/2 Dose-finding, Open-label non-randomized 30 Japan NCT04463472
Themis V591 Replicating viral vector 1/2 Dose-finding, double-blind randomized 260 USA, Austria, Belgium NCT04498247
Inovio INO-4800 DNA 1/2 Dose-finding, open-label (A), double-blind (B) randomized 160 Republic of Korea NCT04447781
Novavax NVX-CoV2373 Protein subunit 1/2 Dose-finding, observer-blind randomized 1,419 Australia, USA NCT04368988
Imperial LNP-nCoVsaRNA RNA 1 Dose-finding partially randomized 320 UK ISRCTN17072692
Medicago CoVLP Virus-like particle 1 Dose-finding, open-label randomized 180 Canada NCT04450004
Curevac CVnCoV RNA 1 Dose-finding, single-blind randomized 284 Belgium, Germany NCT04449276
PLA-AMS ARCoV RNA 1 Dose-finding randomized 168 China ChiCTR2000034112
Moderna mRNA-1273 RNA 1 Dose-finding, open-label non-randomized 120 USA NCT04283461
Clover SCB-2019 Protein subunit 1 Dose-finding, double-blind randomized 150 Australia NCT04405908
BioNTech BNT162 RNA 1 Double-blind randomized 144 China NCT04523571
Inovio INO-4800 DNA 1 Dose-finding, open-label non-randomized 120 USA NCT04336410
University of Queensland vaccine Protein subunit 1 Dose-finding, double-blind randomized 216 Australia NCT04495933
Symvivo bacTRL-Spike DNA 1 Dose-finding, observer-blind randomized 12 Australia NCT04334980
Cansino Ad5-nCoV Non-replicating viral vector 1 Dose-finding, open-label non-randomized 108 China NCT04313127
SGMI aAPC Other 1 Open-label non-randomized 100 China NCT04299724
SGMI LV-SMENP-DC Other 1 Open-label non-randomized 100 China NCT04276896
Themis V591 Replicating viral vector 1 Dose-finding, double-blind randomized 90 Belgium, France NCT04497298
Gamaleya Gam-COVID-Vac (Lyo) Non-replicating viral vector 1 Open-label non-randomized 38 Russia NCT04437875
AZLB protein subunit vaccine Protein subunit 1 Double-blind randomized 50 China NCT04445194
Medigen MVC-COV1901 Protein subunit 1 Dose finding, open-label non-randomized 45 Taiwan NCT04487210
Vaxine protein subunit vaccine Protein subunit 1 Double-blind randomized 40 Australia NCT04453852

aAPC, artificial antigen presenting cell; AZLB, Anhui Zhifei Longcom Biopharmaceutical; BIBP, Beijing Institute of Biological Products; CAMS, Chinese Academy of Medical Sciences; KBP, Kentucky BioProcessing; LV-SMENP-DC, vaccine comprising dendritic cells (DCs) modified with lentivirus (LV) vectors expressing ‘SMENP’ minigene; PLA-AMS, People’s Liberation Army Academy of Military Science; SGMI, Shenzhen Geno-Immune Medical Institute; WIBP, Wuhan Institute of Biological Products.

Biomolecules & Therapeutics 2021;29:1~10 https://doi.org/10.4062/biomolther.2020.178
© Biomolecules & Therapeutics